Katsuki, Fujika http://orcid.org/0000-0002-0822-4776
Yamada, Atsurou
Kondo, Masaki
Sawada, Hanayo
Watanabe, Norio
Akechi, Tatsuo
Funding for this research was provided by:
Special Fund for Agro-scientific Research in the Public Interest (16K12256)
Article History
Received: 13 September 2022
Accepted: 30 January 2023
First Online: 14 February 2023
Declarations
:
: This study was approved by the Ethics Review Committee of Nagoya City University Graduate School of Medical Sciences, Japan (Ref: No 60–17-0001). All participants provided written informed consent to participate in this study.
: Not applicable.
: FK has received speaker fees from Otsuka Pharmaceutical Co., Ltd. AY has received medical fees from Gifu Hospital, speaker fees from Aichi Education and Sports Foundation, Kyowa Pharmaceutical Industry Co., Ltd., Meiji Seika Pharma Co., Ltd, Mental Care Association Japan, Mochida Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and other fees from Nagoya City. HS declares no conflicts of interest. MK reports a grant from Novartis Pharma K.K., personal fees from Shionogi & Co., Ltd., and personal fees from Yoshitomiyakuhin Corporation, outside the submitted work. TA has received lecture fees from Astra Zeneca Co., Ltd., Daiichi Sankyo Co., Ltd., Dainippon-Sumitomo Co., Ltd., Eisai Co., Ltd., Janssen Co., Ltd., Kyowa Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Meiji -Seika Pharma Co., Ltd., Mochida Co., Ltd., Nipro Co., Ltd., Nihon-Zoki Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Co., Ltd., Takeda Co., Ltd., and Tsumura Co., Ltd. TA has received research funds from Daiichi Sankyo Co., Ltd., FUJIFILM RI Pharma Co., Ltd., MSD Co., Ltd., Otsuka Co., Ltd., and Shionogi Co., Ltd. NW has received royalties from Sogensha, Medical View, and Advantage Risk Management. TA has received royalties from the Igaku-shoin. TA is the inventor of the pending patents (2019–017498 & 2020–135195).